LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line
Nicoletta Colombo(University of Milano-Bicocca), Andrés Poveda(Hospital Quirónsalud Barcelona), Radoslav Chekerov(Charité - Universitätsmedizin Berlin), G. Funari(Mario Negri Institute for Pharmacological Research), Alessandra Baldoni(Mario Negri Institute for Pharmacological Research), G-B. Nyvang(Odense University Hospital), Germana Tognon(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Cristina Churruca Galaz(Onkologikoa), Angiolo Gadducci(University of Pisa), Elena Biagioli(Mario Negri Institute for Pharmacological Research), Eliana Rulli(Mario Negri Institute for Pharmacological Research), Nelleke Ottevanger(Radboud University Nijmegen), Alain G. Zeimet(Innsbruck Medical University), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Johanna Mäenpää(Tampere University Hospital), I. Vergote(The European Academy of Gynaecological Surgery), Andrea De Censi(Ente Ospedaliero Ospedali Galliera), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Salomé Riniker(Kantonsspital St. Gallen), Roldano Fossati(Mario Negri Institute for Pharmacological Research)
Cited by 23
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k